Last reviewed · How we verify
Active Comparator: Rivaroxaban+Clopidogrel
This combination uses rivaroxaban (a Factor Xa inhibitor) and clopidogrel (a P2Y12 platelet inhibitor) together to provide dual anticoagulant and antiplatelet effects for thrombotic prevention.
This combination uses rivaroxaban (a Factor Xa inhibitor) and clopidogrel (a P2Y12 platelet inhibitor) together to provide dual anticoagulant and antiplatelet effects for thrombotic prevention. Used for Acute coronary syndrome with high thrombotic risk, Stroke prevention in atrial fibrillation with acute coronary syndrome.
At a glance
| Generic name | Active Comparator: Rivaroxaban+Clopidogrel |
|---|---|
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
| Drug class | Anticoagulant + Antiplatelet combination |
| Target | Factor Xa; P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rivaroxaban inhibits Factor Xa in the coagulation cascade, blocking thrombin generation and clot formation. Clopidogrel irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor. Together, they provide complementary anticoagulant and antiplatelet mechanisms to reduce thrombotic events in high-risk cardiovascular conditions.
Approved indications
- Acute coronary syndrome with high thrombotic risk
- Stroke prevention in atrial fibrillation with acute coronary syndrome
Common side effects
- Bleeding (major or minor)
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Dyspepsia
Key clinical trials
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant (PHASE4)
- Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: